Fennec Pharmaceuticals Inc.
FENC•NASDAQ•Healthcare•Biotechnology

About Fennec Pharmaceuticals

Fennec Pharmaceuticals Inc. operates as a commercial stage biopharmaceutical company in the United States. The company’s product candidate includes PEDMARK, a formulation of sodium thiosulfate for the prevention of platinum-induced ototoxicity in pediatric cancer patients. It sells its products through regional pediatric oncology specialists and medical science liaisons. The company was formerly known as Adherex Technologies Inc. and changed its name to Fennec Pharmaceuticals Inc. in September 2014. Fennec Pharmaceuticals Inc. was incorporated in 1996 and is based in Research Triangle Park, North Carolina.

Company Information

SectorHealthcare
IndustryBiotechnology
CEOJeffrey Hackman
Founded1996
IPO DateJune 5, 2001
Employees32
CountryUnited States
Fiscal YearJanuary - December

Stock Details

ExchangeNASDAQ (NASDAQ)
CurrencyUSD - USD
TypeStock

Contact Information

Websitefennecpharma.com
Phone919 636 4530
Address
68 TW Alexander Drive, PO Box 13628 Research Triangle Park, North Carolina 27709 United States

Corporate Identifiers

CIK0001211583
CUSIP31447P100
ISINCA31447P1009
SIC2836

Leadership Team & Key Executives

Jeffrey S. Hackman
Chief Executive Officer and Director
Robert C. Andrade
Chief Financial Officer
Dr. Pierre S. Sayad M.S., Ph.D.
Chief Medical Officer
Terry Evans
Chief Commercial Officer
Christiana Cioffi M.B.A.
Chief Strategy Officer
Mark Gowland
Controller
Lei Fang
President of Pharstat Inc